Gyros Protein Technologies introduces Gyrolab AAV9 Titer Kit for vector-based cell and gene therapies

Written by Vivian Xie

Peptide synthesis and bioanalytical tool provider Gyros Protein Technologies AB (Uppsala, Sweden) has announced the Gyrolab® AAV9 Titer Kit, a ready-to-use kit for determining the physical titer in adeno-associated virus serotype 9 (AAV9) vector-based cell and gene therapy production.  The AAV9 Titer Kit joins a range of ready-to-use kits in the company’s profile, increasing the company’s ability to offer analytical characterization solutions during the manufacturing and purification of cell and gene therapies. The AAV9 Titer kit complements the Gyrolab AAVC Titer Kit and the HEK 293 HCP Solution for Gyrolab. As a gene delivery vector, the AAV9 serotype is able to cross the blood–brain barrier and target the central nervous system. The...

To view this content, please register now for access

It's completely free